Literature DB >> 26560048

Discovery of a marine-derived bis-indole alkaloid fascaplysin, as a new class of potent P-glycoprotein inducer and establishment of its structure-activity relationship.

Sudhakar Manda1, Sadhana Sharma2, Abubakar Wani2, Prashant Joshi1, Vikas Kumar3, Santosh K Guru2, Sonali S Bharate4, Shashi Bhushan5, Ram A Vishwakarma1, Ajay Kumar6, Sandip B Bharate7.   

Abstract

The screening of IIIM natural products repository for P-gp modulatory activity in P-gp over-expressing human adenocarcinoma LS-180 cells led to the identification of 7 natural products viz. withaferin, podophyllotoxin, 3-demethylcolchicine, agnuside, reserpine, seseberecine and fascaplysin as P-gp inducers. Fascaplysin (6a), a marine-derived bis-indole alkaloid, was the most potent among all of them, showing induction of P-gp with EC50 value of 25 nM. P-gp induction is one of the recently targeted strategy to increase amyloid-β clearance from Alzheimer brains. Thus, we pursued a medicinal chemistry of fascaplysin to establish its structure-activity relationship for P-gp induction activity. Four series of analogs viz. substituted quaternary fascaplysin analogs, D-ring opened quaternary analogs, D-ring opened non-quaternary analogs, and β-carbolinium analogs were synthesized and screened for P-gp induction activity. Among the total of 48 analogs screened, only quaternary nitrogen containing analogs 6a-g and 10a, 10h-l displayed promising P-gp induction activity; whereas non-planar non-quaternary analogs 9a-m, 13a-n, 15a-h were devoid of this activity. The P-gp induction activity of best compounds was then confirmed by western-blot analysis, which indicated that fascaplysin (6a) along with 4,5-difluoro analog of fascaplysin 6f and D-ring opened analog 10j displayed 4-8 fold increase in P-gp expression in LS-180 cells at 1 μM. Additionally, compounds 6a and 6f also showed inhibition of acetylcholinestease (AChE), an enzyme responsible for neuronal loss in Alzheimer's disease. Thus, fascaplysin and its analogs showing promising P-gp induction along with AChE inhibition at 1 μM, with good safety window (LS-180: IC50 > 10 μM, hGF: 4 μM), clearly indicates their promise for development as an anti-Alzheimer agent.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Acetylcholinesterase; Alzheimer's disease; Fascaplysin; P-glycoprotein induction; Quaternary analogs; β-carboline

Mesh:

Substances:

Year:  2015        PMID: 26560048     DOI: 10.1016/j.ejmech.2015.10.049

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  13 in total

1.  Identification of the First Marine-Derived Opioid Receptor "Balanced" Agonist with a Signaling Profile That Resembles the Endorphins.

Authors:  Tyler A Johnson; Laura Milan-Lobo; Tao Che; Madeline Ferwerda; Eptisam Lambu; Nicole L McIntosh; Fei Li; Li He; Nicholas Lorig-Roach; Phillip Crews; Jennifer L Whistler
Journal:  ACS Chem Neurosci       Date:  2016-11-22       Impact factor: 4.418

2.  Synthesis and antitumor activity of aza-brazilan derivatives containing imidazolium salt pharmacophores.

Authors:  Mingqin Huang; Shengzu Duan; Xueqiong Ma; Bicheng Cai; Dongmei Wu; Yan Li; Liang Li; Hongbin Zhang; Xiaodong Yang
Journal:  Medchemcomm       Date:  2019-05-10       Impact factor: 3.597

Review 3.  P-glycoprotein (ABCB1) and Oxidative Stress: Focus on Alzheimer's Disease.

Authors:  Giulia Sita; Patrizia Hrelia; Andrea Tarozzi; Fabiana Morroni
Journal:  Oxid Med Cell Longev       Date:  2017-11-26       Impact factor: 6.543

Review 4.  Cellular Models and In Vitro Assays for the Screening of modulators of P-gp, MRP1 and BCRP.

Authors:  Mariline Gameiro; Renata Silva; Carolina Rocha-Pereira; Helena Carmo; Félix Carvalho; Maria de Lourdes Bastos; Fernando Remião
Journal:  Molecules       Date:  2017-04-08       Impact factor: 4.411

5.  Total Syntheses and Preliminary Biological Evaluation of Brominated Fascaplysin and Reticulatine Alkaloids and Their Analogues.

Authors:  Maxim E Zhidkov; Polina A Smirnova; Oleg A Tryapkin; Alexey V Kantemirov; Yuliya V Khudyakova; Olesya S Malyarenko; Svetlana P Ermakova; Valeria P Grigorchuk; Moritz Kaune; Gunhild von Amsberg; Sergey A Dyshlovoy
Journal:  Mar Drugs       Date:  2019-08-25       Impact factor: 5.118

6.  Aza-Annulation of 1,2,3,4-Tetrahydro-β-carboline Derived Enaminones and Nitroenamines: Synthesis of Functionalized Indolizino[8,7-b]indoles, Pyrido[1,2-a:3,4-b']diindoles, Indolo[2,3-a]quinolizidine-4-ones and Other Tetrahydro-β-carboline Fused Heterocycles.

Authors:  Anusha Avadhani; Pethaperumal Iniyavan; Anand Acharya; Vibha Gautam; Sriparna Chakrabarti; Hiriyakkanavar Ila
Journal:  ACS Omega       Date:  2019-10-16

Review 7.  Benefits under the Sea: The Role of Marine Compounds in Neurodegenerative Disorders.

Authors:  Mariano Catanesi; Giulia Caioni; Vanessa Castelli; Elisabetta Benedetti; Michele d'Angelo; Annamaria Cimini
Journal:  Mar Drugs       Date:  2021-01-08       Impact factor: 5.118

Review 8.  Marine Pharmacology in 2016-2017: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis and Antiviral Activities; Affecting the Immune and Nervous Systems, and Other Miscellaneous Mechanisms of Action.

Authors:  Alejandro M S Mayer; Aimee J Guerrero; Abimael D Rodríguez; Orazio Taglialatela-Scafati; Fumiaki Nakamura; Nobuhiro Fusetani
Journal:  Mar Drugs       Date:  2021-01-21       Impact factor: 5.118

Review 9.  Marine-Derived Compounds with Anti-Alzheimer's Disease Activities.

Authors:  Salar Hafez Ghoran; Anake Kijjoa
Journal:  Mar Drugs       Date:  2021-07-24       Impact factor: 5.118

Review 10.  Marine Natural Products, Multitarget Therapy and Repurposed Agents in Alzheimer's Disease.

Authors:  Márcia Martins; Renata Silva; Madalena M M Pinto; Emília Sousa
Journal:  Pharmaceuticals (Basel)       Date:  2020-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.